Biomarker-based Alzheimer's Disease Cohort Study (BASIC)

Capital Medical University

Status: Enrolling

Conditions: Alzheimer Disease

Treatments: Other: None-placebo

Study type: Observational

Funder types: Other

Identifiers

NCT07109999

2024347

Details and patient eligibility

About

This study adopts a prospective cohort design, constructing a single-center cohort by recruiting patients with Alzheimer's disease (AD) who are positive for AD biomarkers. First, the investigators aim to establish a cohort of AD patients with positive biomarkers, thereby reserving suitable patient resources for future AD-related clinical trials. Second, based on the established cohort, the investigators will explore the associations between AD-related biomarkers and clinical manifestations among the elderly population in China, and identify potential risk factors influencing the progression of AD. Third, according to the identified risk factors for AD progression, the investigators will construct a risk early warning model for the progression rate of AD based on biomarkers, in order to achieve early identification and precise prevention and control of the progression risk of AD.

Enrollment: 2,835 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• (1) Patients aged 40 years or older;
• (2) Visiting Xuanwu Hospital, Capital Medical University;
• (3) Meeting the core clinical diagnostic criteria for Alzheimer's disease (AD) - related mild cognitive impairment or probable AD according to the NIA-AA (2011);
• (4) Amyloid positivity confirmed by amyloid PET or cerebrospinal fluid biomarker tests;
• (5) Providing informed consent.

Exclusion criteria

• (1) Individuals who are unable to complete the assessment due to severe psychological or physiological disorders.

Trial design

2,835 participants in 1 patient group

Patients diagnosed with Alzheimer's disease with AD biomarker positivity.

Description:

This cohort recruits patients diagnosed with Alzheimer's disease based on clinical symptoms, neuroimaging features and AD biomarkers. Biomarker positivity is necessary for inclusion.

Treatment:

Other: None-placebo